Global News

RQx Pharmaceuticals, collaborate on novel drug compounds

Wednesday, February 13, 2013 11:29 AM

RQx Pharmaceuticals, a biopharmaceutical company developing broad-spectrum small molecule antibiotics for serious life-threatening infections, has entered into a drug discovery collaboration with Genentech, a member of the Roche Group, for the discovery and development of novel drug compounds for an undisclosed target.

More... »

Lycera, Merck ink autoimmune collaboration

Wednesday, February 13, 2013 11:01 AM

Lycera, a biopharmaceutical company focused on autoimmune diseases, has signed a collaboration agreement with Merck, to discover, develop and commercialize small-molecule therapies directed to selected novel targets being investigated for the treatment of a broad range of immune-mediated disorders.

More... »

MorphoSys, Heptares to develop antibody therapeutics targeting GPCRs

Wednesday, February 13, 2013 10:03 AM

MorphoSys, a biotechnology company focused on fully human antibodies, and Heptares Therapeutics, a developer of new medicines targeting G protein-coupled receptors (GPCRs), have signed an agreement to discover novel antibody therapeutics targeting GPCRs—membrane proteins involved in a broad range of biological processes and diseases.

More... »

AcelRx appoints Adrian Adams to board

Tuesday, February 12, 2013 08:00 AM

AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on acute and breakthrough pain, has appointed Adrian Adams, CEO and president of Auxilium Pharmaceuticals, to its board of directors as chairman of the board.  

More... »

WCCT Global successfully completes enrollment in ethnobridging study

Monday, February 11, 2013 02:37 PM

WCCT Global, a global CRO supporting phase I-IV bio-pharmaceutical and device development, announced the success of their specialized recruitment methods for ethnobridging studies.

More... »

PPD adds new central laboratory services

Monday, February 11, 2013 10:57 AM

Global CRO Pharmaceutical Product Development (PPD) has expanded its testing capabilities at its Brussels and Singapore labs, offering clients additional microbiology, peripheral blood mononuclear cell and molecular pathology services.

More... »

Cardiome selects Quintiles to manage global regulatory affairs for Brinavess

Monday, February 11, 2013 10:22 AM

Biopharmaceutical company Cardiome Pharma has selected Quintiles, a global provider of biopharmaceutical services, to provide comprehensive post-marketing lifecycle safety and global regulatory affairs services for Brinavess (vernakalant intravenous). Quintiles will begin providing these services effective immediately as Cardiome continues to prepare for the anticipated transfer of Brinavess from Merck to Cardiome.

More... »

Icon, DIA to deliver new educational product

Monday, February 11, 2013 09:53 AM

Icon,a global provider of outsourced development, has formed a collaboration with DIA, a neutral, global, professional, member-driven association of nearly 18,000 pharmaceutical, biotechnology, and medical device professionals, to deliver the first solution-provider webinar, which offers free access to knowledge and innovative solutions to overcome some of the key challenges in medical product development.

More... »

Ampio forms Luoxis Diagnostics to commercialize ORP tech

Monday, February 11, 2013 09:25 AM

Luoxis Diagnostics, a newly incorporated subsidiary of Ampio Pharmaceuticals, a biopharmaceutical company focused on prevalent inflammatory diseases, has initiated its operations that will initially be funded through a private placement, with Ampio maintaining approximately 80% ownership post financing.

More... »

Sun Pharma, Taro terminate proposed merger

Friday, February 8, 2013 01:08 PM

Sun Pharmaceutical Industries, an India-based specialty pharmaceutical company, and Taro Pharmaceutical Industries, a multinational, science-based pharmaceutical company, have  mutually  agreed  to  terminate  their  merger  agreement,  announced  in  August  2012,  pursuant  to which all shareholders of Taro (other than Sun Pharma and its affiliates) would have received a cash payment of $39.50 per share upon the closing of the merger.

More... »